High Incidence of Psychiatric Disorders Associated with Cycloserine Treatment of Multidrug-Resistant Tuberculosis Patients: A Cohort Study in Beijing, China

References

• Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-2
   PubMed Web of Science ®Google Scholar
• Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656–673. doi:10.1111/resp.13304
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. WHO/HTM/TB/2020.
   Google Scholar
• Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect. 2018;76(4):348–353. doi:10.1016/j.jinf.2017.12.017
   PubMed Web of Science ®Google Scholar
• Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(5):e63057. doi:10.1371/journal.pone.0063057
   PubMed Web of Science ®Google Scholar
• Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844–1851. doi:10.1086/588292
   PubMed Web of Science ®Google Scholar
• Harris DA, Ruger M, Reagan MA, et al. Discovery, development, and antimicrobial properties of D-4-amino-3-isoxazolidone (oxamycin), a new antibiotic produced by Streptomyces garyphalus n. sp. Antibiot Chemother. 1955;5(4):183–190.
   Google Scholar
• Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629. doi:10.1016/S1473-3099(10)70139-0
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO operational handbook on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2013;17(10):1257–1266. doi:10.5588/ijtld.12.0863
   PubMed Web of Science ®Google Scholar
• Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;105:688–694. doi:10.1016/j.ijid.2021.03.001
   PubMed Web of Science ®Google Scholar
• Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 2007;12(1):51–6, 59–61. doi:10.1017/s1092852900020526
   Web of Science ®Google Scholar
• Hansen KB, Yi F, Perszyk RE, Menniti FS, Traynelis SF. NMDA receptors in the central nervous system. Methods Mol Biol. 2017;1677:1–80. doi:10.1007/978-1-4939-7321-7_1
   Google Scholar
• Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother. 2019;63(5). doi:10.1128/AAC.00055-19
   Web of Science ®Google Scholar
• Wang J, Pang Y, Jing W, et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist. 2019;12:763–770. doi:10.2147/IDR.S194484
   Web of Science ®Google Scholar
• van der Walt ML, Shean K, Becker P, Keddy KH, Lancaster J. Treatment outcomes and adverse drug effects of ethambutol, cycloserine, and terizidone for the treatment of multidrug-resistant tuberculosis in South Africa. Antimicrob Agents Chemother. 2020;65(1). doi:10.1128/AAC.00744-20
   Web of Science ®Google Scholar
• Li Y, Wang F, Wu L, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infect Drug Resist. 2019;12:721–731. doi:10.2147/IDR.S195555
   Web of Science ®Google Scholar
• Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597–602. doi:10.1016/j.cmi.2020.06.004
   PubMed Web of Science ®Google Scholar
• Division of AIDS, National Institute of allergy and infectious diseases National Institutes of health, US department of health and Human services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events: corrected version 2.1; 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed June 14, 2022.
   Google Scholar
• World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Riccardi N, Giacomelli A, Canetti D, et al. Clofazimine: an old drug for never-ending diseases. Future Microbiol. 2020;15(7):557–566. doi:10.2217/fmb-2019-0231
   Web of Science ®Google Scholar
• Walker WC, Murdoch JM. Cycloserine in the treatment of pulmonary tuberculosis; a report on toxicity. Tubercle. 1957;38(5):297–302. doi:10.1016/S0041-3879(57)80097-X
   Google Scholar
• Epstein IG, Nair KG, Boyd LJ, Auspitz P. Cycloserine-isoniazid combination therapy in virgin cases of pulmonary tuberculosis. Dis Chest. 1958;33(4):371–381. doi:10.1378/chest.33.4.371
   Google Scholar
• Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383–394. doi:10.1016/S2213-2600(20)30047-3
   PubMed Web of Science ®Google Scholar
• Riccardi N, Villa S, Alagna R, et al. Advantages and challenges of tailored regimens for drug-resistant tuberculosis: a StopTB Italia look into the future. Infect Drug Resist. 2020;13:2795–2800. doi:10.2147/IDR.S257480
   PubMed Web of Science ®Google Scholar
• Wu HY, Tian Y, Wang XD, et al. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: a retrospective cohort study in China. J Paediatr Child Health. 2022;58(1):116–121. doi:10.1111/jpc.15672
   PubMed Web of Science ®Google Scholar
• Spiro JE, Brose N, Heinemann SF, Heiligenberg W. Immunolocalization of NMDA receptors in the central nervous system of weakly electric fish: functional implications for the modulation of a neuronal oscillator. J Neurosci. 1994;14(10):6289–6299. doi:10.1523/JNEUROSCI.14-10-06289.1994
   Web of Science ®Google Scholar
• Price M, Yuen EK, Goetter EM, et al. mHealth: a mechanism to deliver more accessible, more effective mental health care. Clin Psychol Psychother. 2014;21(5):427–436. doi:10.1002/cpp.1855
   PubMed Web of Science ®Google Scholar